ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.